Press releasePRNewswire
VolitionRX
VNRX · NYSE American
$0.1732−$0.0006 (−0.35%)TodayMarket closed ·
Prev close $0.1738
Latest news
- Press releasePRNewswire
VolitionRx Participates in Launch of DETECSEPS Program in France
- Press releasePRNewswire
VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
- Press releasePRNewswire
Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results
- NewsVandana Singh
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
- NewsAvi Kapoor
Why Salesforce Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
- Press releasePRNewswire
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- Press releasePRNewswire
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
- News
VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript
- Press releasePRNewswire
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
- Press releasePRNewswire
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
- Press releasePRNewswire
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
- Press releasePRNewswire
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
- Press releasePRNewswire
Volition Advances Nu.Q® NETs Platform Towards Commercialization
- Press releasePRNewswire
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
- Press releasePRNewswire
VolitionRx Announces Collaboration with Sysmex
- Press releasePRNewswire
VolitionRx Announces Pricing of $4.6 Million Public Offering
- Press releasePRNewswire
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
- Press releasePRNewswire
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- News
Full Transcript: VolitionRX Q1 2026 Earnings Call
- Press releasePRNewswire
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
- News
Earnings Scheduled For May 14, 2026
- Press releasePRNewswire
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
- Press releasePRNewswire
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
- Press releasePRNewswire
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
- Press releasePRNewswire
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
- Press releasePRNewswire
Volition Launches rNuQ™ Webshop Broadening Product Range
- Press releasePRNewswire
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
- Press releasePRNewswire
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
- Press releasePRNewswire
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
- NewsAvi Kapoor
Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.